Black Hawk Acquisition Corp
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Black Hawk Acquisition has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Black Hawk Acquisition filed with the SEC
Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Hawk Acquisition Corporation Amends Its Definitive Proxy Statement
Other events · EX-99.1 to Form 8-K
Hawk Acquisition Corporation Amends Its Definitive Proxy Statement
Other events · EX-99.1 to Form 8-K
Hawk Acquisition Corporation Welcomes Mr. Jonathan Ginsberg to Board
Executive or director change · Other events · EX-99.1 to Form 8-K/A
Hawk Acquisition Corporation Welcomes Mr. Jonathan Ginsberg to Board
Executive or director change · Other events · EX-99.1 to Form 8-K
Report of Independent Registered Public Accounting Firm (PCAOB ID: 206)
Other events · EX-99.1 to Form 8-K
Corporation Announces Pricing of $69,000,000
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EF Hutton LLC (“EF Hutton”) acted as sole book running manager in the offering. Celine & Partners, P.L.L.C. served as legal counsel to the Company. Robinson & Cole LLP served as counsel to EF Hutton.
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K